Incidence of Type 2 Diabetes Using Proposed HbA1c Diagnostic Criteria in the European Prospective Investigation of Cancer–Norfolk Cohort
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate the incidence and relative risk of type 2 diabetes defined by the newly proposed HbA1c diagnostic criteria in groups categorized by different baseline HbA1c levels. RESEARCH DESIGN AND METHODS: Using data from the European Prospective Investigation of Cancer (EPIC)-Norfolk cohort with repeat HbA1c measurements, we estimated the prevalence of known and previously undiagnosed diabetes at baseline (baseline HbA1c ≥6.5%) and the incidence of diabetes over 3 years. We also examined the incidence and corresponding odds ratios (ORs) by different levels of baseline HbA1c. Incident diabetes was defined clinically (self-report at follow-up, prescribed diabetes medication, or inclusion on a diabetes register) or biochemically (HbA1c ≥6.5% at the second health assessment), or both. RESULTS: The overall prevalence of diabetes was 4.7%; 41% of prevalent cases were previously undiagnosed. Among 5,735 participants without diabetes at baseline (identified clinically or using HbA1c criteria, or both), 72 developed diabetes over 3 years (1.3% [95% CI 1.0–1.5]), of which 49% were identified using the HbA1c criteria. In 6% of the total population, the baseline HbA1c was 6.0–6.4%; 36% of incident cases arose in this group. The incidence of diabetes in this group was 15 times higher than in those with a baseline HbA1c of <5.0% (OR 15.5 [95% CI 7.2–33.3]). CONCLUSIONS: The cumulative incidence of diabetes defined using a newly proposed HbA1c threshold in this middle-aged British cohort was 1.3% over 3 years. Targeting interventions to individuals with an HbA1c of 6.0–6.4% might represent a feasible preventive strategy, although complementary population-based preventive strategies are also needed to reduce the growing burden of diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s062 · Cited by 5,491
The Finnish Diabetes Prevention Study (DPS)
Lindström, J., Louheranta, A., Mannelin, M., Rastas, M., Salminen, V., Eriksson, J., Uusitupa, M., Tuomilehto, J., & for the Finnish Diabetes Prevention Study Group (2003) · Diabetes Care · doi:10.2337/diacare.26.12.3230 · Cited by 1,848
Li, G., Zhang, P., Wang, J., Gregg, E. W., Yang, W., Gong, Q., Li, H., Li, H., Jiang, Y., An, Y., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60766-7 · Cited by 1,600 · cited 1×
“(1) It is possible to halve the incidence of type 2 diabetes among individuals at high risk through lifestyle and pharmacological interventions.(2-4) However, it is unlikely that population screening for impaired glucose tolerance using an oral glucose tolerance test (OGTT) is a feasible method of identifying those at…”
BackgroundGlycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults
Selvin, E., Steffes, M. W., Zhu, H., Matsushita, K., Wagenknecht, L., Pankow, J., Coresh, J., & Brancati, F. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908359 · Cited by 1,544
Khaw, K.-T., Wareham, N., Bingham, S., Luben, R., Welch, A., & Day, N. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00006 · Cited by 974 · cited 1×
“Glycated hemoglobin (HbA1c) is a reliable measure of long-term glycemic exposure (8) that correlates well with the risk of microvascular and macrovascular complications of diabetes (9,10).”
BackgroundSelf-citationGlobal Estimates for Prevalence of Diabetes Mellitus and Impaired Glucose Tolerance in Adults
King, H., Rewers, M., & Who Ad Hoc Diabetes Reporting Group (1993) · Diabetes Care · doi:10.2337/diacare.16.1.157 · Cited by 886
Day, N., Oakes, S., Luben, R., Khaw, K., Bingham, S., Welch, A., & Wareham, N. (1999) · Nature · doi:10.17863/cam.89388 · Cited by 780
Self-citationHerman, W. H., Hoerger, T. J., Brandle, M., Hicks, K., Sorensen, S., Zhang, P., Hamman, R. F., Ackermann, R. T., Engelgau, M. M., Ratner, R. E., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-5-200503010-00007 · Cited by 703
Cited by
Type 2 Diabetes Mellitus: A Review of Current Trends
Olokoba, A. B., Obateru, O. A., & Olokoba, L. B. (2012) · Oman Medical Journal · doi:10.5001/omj.2012.68 · Cited by 1,338
Imamura, F., Micha, R., Wu, J. H. Y., de Oliveira Otto, M. C., Otite, F. O., Abioye, A. I., & Mozaffarian, D. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002087 · Cited by 479
Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia
Richter, B., Hemmingsen, B., Metzendorf, M.-I., & Takwoingi, Y. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012661.pub2 · Cited by 283
Heianza, Y., Hara, S., Arase, Y., Saito, K., Fujiwara, K., Tsuji, H., Kodama, S., Hsieh, S. D., Mori, Y., Shimano, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60472-8 · Cited by 260
Reactive oxygen species: sources, consequences and targeted therapy in type 2 diabetes
Panigrahy, S. K., Bhatt, R., & Kumar, A. (2017) · Journal of Drug Targeting · doi:10.1080/1061186x.2016.1207650 · Cited by 103
Metadata
- Authors
- Chamnan, P., Simmons, R. K., Forouhi, N. G., Luben, R. N., Khaw, K.-T., Wareham, N. J., & Griffin, S. J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-03-21
- Volume
- 34
- Issue
- 4
- Pages
- 950-956
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2099917767
- Cited by
- 78
- References
- 14
- FWCI
- 2.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Incidence of Type 2 Diabetes Using Proposed HbA1c Diagnostic Criteria in the European Prospective Investigation of Cancer–Norfolk Cohort. https://app.cochat.ai/papers/10.2337/dc09-2326
- The paper
- Chamnan, P., Simmons, R. K., Forouhi, N. G., Luben, R. N., Khaw, K.-T., Wareham, N. J., & Griffin, S. J. (2011). Incidence of Type 2 Diabetes Using Proposed HbA1c Diagnostic Criteria in the European Prospective Investigation of Cancer–Norfolk Cohort. Diabetes Care. https://doi.org/10.2337/dc09-2326
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.